Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug

Executive Summary

Avillion – which seeks co-development deals for products that otherwise could languish in busy big pharma pipelines – is taking on development of Merck's early-stage psoriasis drug, M1095, despite originator Ablynx having opted out of a co-development arrangement with the German firm for the drug four years earlier.


Related Content

Multispecific Approach Could Improve I-O Side Effect Profile, Says Numab
Deal Watch: Merck, Incyte Double Down On Keytruda/Epacadostat Collaboration


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts